CytomX Therapeutics (CTMX) Reports Q3 Loss, Lags Revenue Estimates
Aytu Biopharma Inc AYTU
$1.84
▲ +2.79%
(+$0.05)
⚡ High Volume
🎈 Low Float
📅 Earnings This Week
Open
$1.80
Prev Close
$1.79
Day Range
$1.78 – $1.86
52W Range
$1.75 – $3.07
Market Cap
$19.45M
Beta
0.27
EPS (TTM)
$-1.49
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2017-10-20 |
| Shares Out. | 10,870,000 |
| Website | aytubio.com/ ↗ |
| Phone | 13026365400 |
| Employees | 76 |
| Revenue | $16.1M |
| Gross Profit | $10.4M |
| Net Income | -$15,000 |
| Free Cash Flow | $3.3M |
| Total Assets | $105.0M |
| Total Liabilities | $69.7M |
| Equity | $35.3M |
About Aytu Biopharma Inc
Aytu BioPharma Inc is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. It has single operating segment. Its product portfolio includes EXXUA, ADHD Portfolio, Pediatric Portfolio, and Other. Majority of revenue comes from ADHD Portfolio. It has presence in United States.
Aytu Biopharma Inc is a publicly traded company under the ticker symbol AYTU on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
9 analysts (2026-11-01)